company background image
A226950 logo

OliX Pharmaceuticals KOSDAQ:A226950 Stock Report

Last Price

₩17.33k

Market Cap

₩294.2b

7D

0.3%

1Y

2.1%

Updated

04 Oct, 2024

Data

Company Financials

OliX Pharmaceuticals, Inc

KOSDAQ:A226950 Stock Report

Market Cap: ₩294.2b

A226950 Stock Overview

Focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases.

A226950 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

OliX Pharmaceuticals, Inc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for OliX Pharmaceuticals
Historical stock prices
Current Share Price₩17,330.00
52 Week High₩21,150.00
52 Week Low₩8,280.00
Beta0.81
11 Month Change11.66%
3 Month Change90.02%
1 Year Change2.12%
33 Year Change-48.42%
5 Year Change-5.94%
Change since IPO-47.16%

Recent News & Updates

Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower

Aug 22
Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower

We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

Jul 22
We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

Jun 25
It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

Recent updates

Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower

Aug 22
Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower

We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

Jul 22
We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

Jun 25
It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Apr 13
OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

Feb 17
Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

Shareholder Returns

A226950KR BiotechsKR Market
7D0.3%1.3%-2.8%
1Y2.1%44.1%4.7%

Return vs Industry: A226950 underperformed the KR Biotechs industry which returned 45.5% over the past year.

Return vs Market: A226950 underperformed the KR Market which returned 4.8% over the past year.

Price Volatility

Is A226950's price volatile compared to industry and market?
A226950 volatility
A226950 Average Weekly Movement13.3%
Biotechs Industry Average Movement9.4%
Market Average Movement6.8%
10% most volatile stocks in KR Market12.1%
10% least volatile stocks in KR Market3.5%

Stable Share Price: A226950's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A226950's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
201072Dong-Ki Leewww.olixpharma.com

OliX Pharmaceuticals, Inc. focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX201A for idiopathic pulmonary fibrosis; OLX301 for age-related macular degeneration; and OLX301D for subretinal fibrosis. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA.

OliX Pharmaceuticals, Inc Fundamentals Summary

How do OliX Pharmaceuticals's earnings and revenue compare to its market cap?
A226950 fundamental statistics
Market cap₩294.16b
Earnings (TTM)-₩19.72b
Revenue (TTM)₩17.90b

16.4x

P/S Ratio

-14.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A226950 income statement (TTM)
Revenue₩17.90b
Cost of Revenue₩222.79m
Gross Profit₩17.68b
Other Expenses₩37.40b
Earnings-₩19.72b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.16k
Gross Margin98.76%
Net Profit Margin-110.18%
Debt/Equity Ratio166.8%

How did A226950 perform over the long term?

See historical performance and comparison